CD274 and diffuse large B-cell lymphoma: To date, PD-1/PD-L1 blockage therapy has been approved only for primary mediastinal large B cell lymphomas, a rare variant of DLBCL carrying 9p24.1 copy number gains in 29-55% of the cases [101], where pembrolizumab administration have shown encouraging results in clinical trials [102].